Consequently, PTPN1 inhibitors are potential candidates for the treatment of metabolic diseases, including but not limited to fatty liver, obesity, type 2 diabetes and cardiovascular disease.15, 16. This evidence concerns the gene PTPN1 and obesity due to melanocortin 4 receptor deficiency.